Systemic Sclerosis Market Is Set To Grow At A Remarkable CAGR During The Forecast Period (2023-32) – Asserts Delveinsight | Eicos Sciences, Cytori Therapeutics, Corbus Pharmaceuticals

Systemic Sclerosis Market Is Set To Grow At A Remarkable CAGR During The Forecast Period (2023-32) - Asserts Delveinsight | Eicos Sciences, Cytori Therapeutics, Corbus Pharmaceuticals
Delveinsight Business Research LLP
According to DelveInsight, the Systemic Sclerosis Market is poised for significant growth in the upcoming years, driven by a surge in prevalence, continuous advancements in treatment modalities, and the introduction of novel therapies to the market. The rising incidence of systemic sclerosis underscores the urgent need for innovative solutions, making the market a focal point for pharmaceutical and biotechnology companies.

DelveInsight’s “Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Systemic Sclerosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan). 

The report covers emerging Systemic Sclerosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Systemic Sclerosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Systemic Sclerosis: An Overview

Systemic Sclerosis (SSc) is a rare condition presenting with various visceral manifestations, including peripheral vascular, digestive, cardiopulmonary, and renal involvement. The disease is characterized by microcirculation anomalies, with debates ongoing about potential macrocirculation abnormalities. Fibrotic lesions can manifest on the skin and/or internally. Cutaneous sclerosis lesions may appear modest and distal, often affecting the fingers and areas around the mouth. In some cases, these lesions extend beyond the elbows and knees, and more rarely, they may reach the torso and abdomen. 

 Additionally, a unique form known as “sine scleroderma” exists, which lacks cutaneous involvement altogether. The intricacies of SSc highlight the need for a comprehensive understanding of its diverse manifestations, paving the way for targeted therapeutic approaches and improved patient care. Ongoing research into both cutaneous and visceral aspects contributes to unraveling the complexities of this challenging disease.

The physiopathology of SSc is complex and still poorly understood, being associated with endothelial cell, fibroblastic, and immune system dysfunction.

Systemic Sclerosis Market Key Facts

  • According to DelveInsights’ estimations, the number of diagnosed prevalent cases of systemic sclerosis in the 7MM was approximately 150,000 cases in 2022. It is projected to increase during the study period until 2032. Among this, 47% of the cases originated from the US.

  • EU4 and the UK represented approximately 59,000 diagnosed prevalent cases of systemic sclerosis. Among these cases, the United Kingdom accounted for the highest number, with an estimated 15,000 diagnosed prevalent cases, while Germany was anticipated to have the lowest number of cases in EU4 and the UK.

  • Japan accounted for 14% of the total diagnosed prevalent cases of systemic sclerosis in the 7MM in 2022, with approximately 20,000 cases.

  • According to a study by Barnes et al. (2012), among the 284 deceased patients, 54.6% had diffuse cutaneous disease (dcSSc), and 40.5% had limited cutaneous disease (lcSS). The median disease duration was 7.1 years for dcSSc and 15 years for lcSSc.

  • As per the literature review by Coi et al. (2021), SSc was predominant (86.7% of the total) in females, with an overall sex ratio F/M of 6.5.

  • SSc usually appears in women aged 30–40, and it occurs in slightly older men. In approximately 85% of cases, systemic sclerosis develops in individuals aged 20–60.

  • SSc predominantly affects women (three to eight women for each man). It occurs most frequently between the ages of 45 and 64 years. The prevalence of SSc is still poorly understood.

Systemic Sclerosis Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Systemic Sclerosis pipeline therapies. It also thoroughly assesses the Systemic Sclerosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

 The report gives complete details of the market trend for each marketed Systemic Sclerosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Systemic Sclerosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Systemic Sclerosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Systemic Sclerosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Systemic Sclerosis Epidemiology, Segmented as –

  • Prevalent Cases of Systemic Sclerosis

  • Diagnosed Prevalent Cases of Systemic Sclerosis

  • Gender-specific Diagnosed Prevalent Cases of Systemic Sclerosis

  • Age-specific Diagnosed Prevalent Cases of Systemic Sclerosis

  • Type-specific Diagnosed Prevalent Cases of Systemic Sclerosis

Systemic Sclerosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Systemic Sclerosis market or expected to be launched during the study period. The analysis covers the Systemic Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Systemic Sclerosis drugs based on their sale and market share.

The report also covers the Systemic Sclerosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Systemic Sclerosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Systemic Sclerosis Market Will Evolve and Grow by 2032 @

Systemic Sclerosis Therapeutics Analysis

No treatment has been proven to modify the overall disease course, but the therapy targets specific organ involvement early before irreversible damage to improve both quality of life and survival. The therapeutic market is driven by the increase in prevalent cases and is mainly driven by the patient pools of 30–50 years. The therapeutic market size is accounted for therapies directed toward the management of specific symptoms, and current therapies use medications that focus on the four main features of the disease: inflammation, autoimmunity, vascular disease, and tissue fibrosis. 

Currently, immunosuppressive agents such as methotrexate, cyclophosphamide, mycophenolate mofetil, Azathioprine; autologous stem cell transplantation, and others are therapeutic choices for Systemic Sclerosis.

Treatment of Systemic Sclerosis varies according to the manifestation such as cutaneous, pulmonary, gastric, heart, and renal, and most of the therapies aim to treat the specific organ involvement to avoid irreversible damage as well as to improve both qualities of life and survival.

To further improve the treatment scenario, currently, several major pharma and biotech companies are developing therapies for Systemic Sclerosis to improve the treatment outcome. Currently, Eicos Sciences is leading the therapeutics market with its Systemic Sclerosis drug candidates in the most advanced stage of clinical development.

Systemic Sclerosis Companies Actively Working in the Therapeutics Market Include

Acceleron Pharma, Accuitis Pharmaceuticals, AKL Research and Development, AnaMar, arGentis Pharmaceuticals, ASKA Pharmaceutical, Atlantic Healthcare, Bayer, Beijing Continent Pharmaceutical, Blade Therapeutics, BriaCell Therapeutics, Bristol-Myers Squibb, Camurus, Cantargia, Castle Creek Biosciences, Certa Therapeutics, Chemomab therapeutics, Corbus Pharmaceuticals, CSL Behring, Cumberland Pharmaceuticals, Cytori therapeutics, D&D Pharmatech, Eicos Sciences, Emerald Health Pharmaceuticals, Formation Biologics, Gesynta Pharma, GlaxoSmithKline, Horizon Pharmaceuticals, Horizon Therapeutics, iBio, ILTOO Pharma, Janssen Biotech, Kadmon Pharmaceuticals, Kyowa Kirin, Leadiant Biosciences, Mitsubishi Tanabe Pharma, Pfizer, Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Riptide Bioscience, Sanofi, Seagen, Talaris Therapeutics, Timber Pharmaceuticals, Tvardi Therapeutics, United Therapeutics, Vicore Pharma, Viela Bio, Zenyaku Kogyo, and many others.

Emerging and Marketed Systemic Sclerosis Therapies Covered in the Report Include:

  • Iloprost: Eicos Sciences

  • ECCS 50: Cytori therapeutics

  • Lenabasum (JBT-101): Corbus Pharmaceuticals

  • EHP-101: Emerald Health Pharmaceuticals

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Systemic Sclerosis Competitive Intelligence Analysis

4. Systemic Sclerosis Market Overview at a Glance

5. Systemic Sclerosis Disease Background and Overview

6. Systemic Sclerosis Patient Journey

7. Systemic Sclerosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Systemic Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Systemic Sclerosis Unmet Needs

10. Key Endpoints of Systemic Sclerosis Treatment

11. Systemic Sclerosis Marketed Therapies

12. Systemic Sclerosis Emerging Drugs and Latest Therapeutic Advances

13. Systemic Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Systemic Sclerosis Market Outlook (In US, EU5, and Japan)

16. Systemic Sclerosis Companies Active in the Market

17. Systemic Sclerosis Access and Reimbursement Overview

18. KOL Views on the Systemic Sclerosis Market

19. Systemic Sclerosis Market Drivers

20. Systemic Sclerosis Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Metrorrhagia Market

“Metrorrhagia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Metrorrhagia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Metrorrhagia market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States